Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Solvay Pharmaceuticals has signed a product license agreement under which Jazz Pharmaceuticals will have the right to market Luvox tablets and fluvoxamine maleate extended-release capsules in the US.
Subscribe to our email newsletter
Solvay Pharmaceuticals will retain the right to market both products in other territories around the world.
Solvay's Luvox, also known as fluvoxamine, was introduced in 1983 in Europe as one of the very first selective serotonin reuptake inhibitors (SSRI). This class of compounds is used for the treatment of depression, anxiety and other related disorders. Fluvoxamine was later introduced in the US in 1994.
More recently, Solvay submitted a new drug application in April 2006 to the FDA for fluvoxamine maleate extended-release capsules, an investigational compound being studied for the treatment of generalized social anxiety disorder and obsessive compulsive disorder in adults.
The clinical data supporting the application is based on three clinical trials evaluating the efficacy and safety of the compound.